People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alumis Inc. | — | Biotechnology | Series D+ | $240.0M | $433.1M | 2024 |
| Endo, Inc. | — | Pharmaceuticals | Series D+ | $170.6M | $2.0B | 2024 |
| Players Network | — | Other | Pre-Seed | $1.0M | $23.1M | 2010 |
Mark Bradley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Bradley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Srinivas Akkaraju | 1 | 10 |
| Richard Gaster | 1 | 7 |
| Alan Colowick | 1 | 7 |
| James Tananbaum | 1 | 6 |
| James B. Tananbaum | 1 | 4 |
| Patrick Barry | 1 | 4 |
| Vikram Bajaj | 1 | 3 |
| Michael Rome | 1 | 3 |
| June Lee | 1 | 3 |
| Sapna Srivastava | 1 | 3 |
| Alan B. Colowick | 1 | 3 |
| Paul Efron | 1 | 3 |
| John R. Schroer | 1 | 2 |
| Scott Hirsch | 1 | 2 |
| Zhengbin Yao | 1 | 2 |
| Matthew Maletta | 1 | 2 |
| Doug Miller | 1 | 2 |
| MARTIN BABLER | 1 | 2 |
| Michael Berk | 1 | 1 |
| Srinivas R. Akkaraju | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.